Previous 10 | Next 10 |
Calliditas Therapeutics: Interim Report Q3, 2021 A quarter of deal making and regulatory review PR Newswire STOCKHOLM , Nov. 18, 2021 /PRNewswire/ -- "Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured proc...
Calliditas announces poster presentations at ASN Digital Kidney Week 2021 PR Newswire STOCKHOLM , Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning N...
Gainers: Kiniksa Pharmaceuticals (NASDAQ:KNSA) +13%, Ocugen (NASDAQ:OCGN) +13%, Calliditas Therapeutics (NASDAQ:CALT) +11%, Context Therapeutics (NASDAQ:CNTX) +10%, Bone Biologics (OTCPK:BBLG) +7%. Losers: ABVC BioPharma (NASDAQ:ABVC) -32%, Semler ...
Calliditas Therapeutics' nomination committee for the AGM 2022 PR Newswire STOCKHOLM , Nov. 2, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2022. The nomination committee, whic...
Gainers: Cadence Bancorporation (NYSE:CADE) +43%. A10 Networks ATEN +30%. GH Research (NASDAQ:GHRS) +25%. Retail Value (NYSE:RVI) +23%. WiMi Hologram WIMI +23%. Greenidge (NASDAQ:GREE) +19%. Aspen Aerogels ASPN +18%. Bel Fuse BELFB +18%. Ramaco Resources (NASDAQ:METC) +16%...
Gainers: G Medical Innovations (NASDAQ:GMVD) +15%, Accuray (NASDAQ:ARAY) +14%, Xeris Biopharma (NASDAQ:XERS) +9%, DURECT (NASDAQ:DRRX) +9%, Ocugen (NASDAQ:OCGN) +7%. Losers: CareDx (NASDAQ:CDNA) -25%, 4D Molecular Therapeutics (NASDAQ:FDMT) -2...
Calliditas announces acquisition of remaining Genkyotex minority shares PR Newswire STOCKHOLM , Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100...
A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs ma...
Updated regulatory timeline for review of MAA in Europe PR Newswire STOCKHOLM , Sept. 16, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq: CALT), a biopharma company focused on identifying...
Gainers: Ampio Pharmaceuticals (NYSE:AMPE) +22%, 180 Life Sciences (NASDAQ:ATNF) +17%, Brainstorm Cell Therapeutics (NASDAQ:BCLI) +15%, Instil Bio (NASDAQ:TIL) +16%, G Medical Innovations (NASDAQ:GMVD) +15%. Losers: Nuwellis (NASDAQ:NUWE) -26%...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...